Search...
H.C. Wainwright Remains a Buy on Immunic (IMUX)
I'm PortAI, I can summarize articles.
H.C. Wainwright's Matthew Caufield reiterated a Buy rating on Immunic (IMUX) with a price target of $8.00. Caufield, a 5-star analyst with a 16.9% average return, focuses on the Healthcare sector. Immunic has a Strong Buy consensus with a $4.25 price target consensus.
In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on Immunic, with a price target of $8.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
According to TipRanks, Caufield is a 5-star analyst with an average return of 16.9% and a 46.95% success rate. Caufield covers the Healthcare sector, focusing on stocks such as Immunic, Opus Genetics, and LENZ Therapeutics.
Immunic has an analyst consensus of Strong Buy, with a price target consensus of $4.25.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments